A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Northern Cancer Institute /ID# 166138, St Leonards

Austin Hospital /ID# 166137, Heidelberg

Monash Health /ID# 217435, Clayton

Northshore University Health System Dermatology Clinical Trials Unit /ID# 201095, Skokie

University of Chicago /ID# 166064, Chicago

Washington University-School of Medicine /ID# 214955, St Louis

Highlands Oncology Group /ID# 166132, Springdale

South Texas Accelerated Research Therapeutics /ID# 166134, San Antonio

The Angeles Clinic and Researc /ID# 166133, Los Angeles

University of California, Davis Comprehensive Cancer Center /ID# 215012, Sacramento

Sheba Medical Center /ID# 166398, Ramat Gan

Northwestern University Feinberg School of Medicine /ID# 165191, Chicago

University of Kentucky Markey Cancer Center /ID# 217665, Lexington

Dana-Farber Cancer Institute /ID# 212920, Boston

Columbia Univ Medical Center /ID# 167184, New York

Stony Brook University Hospital /ID# 216976, Stony Brook

Duke University Medical Center /ID# 166135, Durham

Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600, Providence